Liquiritin Alleviates Depression-Like Behavior in CUMS Mice by Inhibiting Oxidative Stress and NLRP3 Inflammasome in Hippocampus

Abstract

Objective. Central inflammation is generally accepted to be involved in the pathology of depression. We investigated whether liquiritin exerts antidepressant effects by inhibiting central NLRP3 inflammasomes. Results. The behavioral despair model and chronic unpredictable mild stress (CUMS) model in mice were established to evaluate the antidepressant action of liquiritin. In the despair model study, liquiritin (40 mg/kg) administration reduced immobility time in tail suspension test (TST) and forced swimming test (FST) without affecting locomotion activity. In CUMS model study, liquiritin (40 mg/kg, once daily for 4 weeks) significantly increased sucrose consumption and body weight of CUMS mice. The behavioral experiment results showed that liquiritin reduced the immobile time of CUMS mice in TST and FST, respectively, and increased the time spent and open arm entries in the elevated plus-maze (EPM) test. Further, the hippocampal superoxide dismutase (SOD) activity was increased in liquiritin-treated group, while malonaldehyde (MDA) decreased. Additionally, the hippocampal cytokines interleukin-18 (IL-18) and interleukin-1 beta (IL-1β) contents were reduced in the liquiritin-treated group. Further, liquiritin downregulated the expression of NLRP3 in the hippocampus of CUMS mice rather than TLR4. Besides, NLRP3 inflammasome-associated proteins caspase-1 and ASC were also downregulated. However, liquiritin did not alter the thermal stability of NLRP3 in the cellular thermal shift assay (CETSA), suggesting that its inhibition of NLPR3 was not by direct targeting of NLRP3 protein. Conclusions. Liquiritin attenuates depression-like behavior of CUMS mice and inhibited cytokines levels triggered by NLRP3 inflammasome, suggesting the antidepressant action is, at least partially, associated with antioxidant stress and inhibition of NLRP3 inflammasome activation.

Chemical characterization and metabolic profiling of Xiao-Er-An-Shen Decoction by UPLC-QTOF/MS

“…P83 Umbelliferone (Zagaja et al, 2022) and P111 Neohesperidin (Chakraborty et al, 2021) have been reported to exhibit neuroprotective effects. P136 Liquiritigenin (Liu et al, 2022), P116 Tenuifoliside A (Dong et al, 2014), P73 Polygalaxanthone III (Du et al, 2022), P53 Loganin (Pan et al, 2021) and P151 Natsudaidain 3-(4-O-3-Hydroxy-3-Methylglutaroylglucoside) (Okuyama et al, 2017) have been shown to exert their effects through various mechanisms, including changes in neurotransmitter levels, increased cAMP levels and amelioration of locomotor hyperactivity…”

The effectiveness and safety of herbal medicine on suicidal behavior: A PRISMA-compliant systematic review and meta-analysis

“…[ 58 ] Another major component of this herb, liquiritin, exerts antidepressant effects by reducing oxidative stress and neuroinflammation. [ 59 ] B falcatum L. has antidepressant effects associated with increased serum nerve growth factor and brain-derived neurotrophic factor, [ 60 ] relieving oxidative stress, regulating the HPA axis, and protecting neurons. [ 61 ] Furthermore, the antidepressant activity of this herb has been implicated in the central adrenergic mechanism [ 62 ] the serotonergic and noradrenergic systems.…”

Potential antidepressant effects of Traditional Chinese botanical drug formula Chaihu-Shugan-San and its active ingredients

“…This indicates that Glycyrrhizin may exert its antidepressant effects by inhibiting the activation of microglial cells, suppressing the release of pro-inflammatory cytokines, and protecting dendritic spine morphology in the hippocampal region ( Chen et al, 2020 ). Research also suggests that Glycyrrhizin exerts its antidepressant effects in part by inhibiting the levels of cytokines triggered by the NLRP3 inflammasome, highlighting the role of antioxidative stress and the inhibition of NLRP3 inflammasome activation in antidepressant properties of Glycyrrhizin ( Liu et al, 2022a ). Glycyrrhizin is applicable in various depression models, as it can reduce the levels of FSH and estradiol E2 in the serum, improve the decreased 5-HT and NE levels in the hypothalamus, and increase the levels of monoamine neurotransmitters, thereby ameliorating depressive-like behavior in perimenopausal rats ( Lan et al, 2020 ).…”